MX2011007192A - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX2011007192A MX2011007192A MX2011007192A MX2011007192A MX2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A MX 2011007192 A MX2011007192 A MX 2011007192A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- bortezumib
- containing pharmaceutical
- composition
- yrazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica parenteral que comprende cantidades terapéuticamente efectivas de ácido N-(2-pirazina) carbonil-L-fenilalanina-L-leucina borónico o sus sales o sus derivados y trometamina en donde la composición es estable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN58MU2009 | 2009-01-09 | ||
PCT/IN2010/000015 WO2010089768A2 (en) | 2009-01-09 | 2010-01-08 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011007192A true MX2011007192A (es) | 2011-10-04 |
Family
ID=42542466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011007192A MX2011007192A (es) | 2009-01-09 | 2010-01-08 | Composicion farmaceutica. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9095514B2 (es) |
EP (1) | EP2379077A4 (es) |
JP (1) | JP5689816B2 (es) |
KR (1) | KR20110114562A (es) |
CN (1) | CN102292086B (es) |
AU (1) | AU2010211981A1 (es) |
CA (1) | CA2748921A1 (es) |
EA (1) | EA201170921A1 (es) |
MX (1) | MX2011007192A (es) |
WO (1) | WO2010089768A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
NZ602392A (en) | 2010-03-18 | 2014-03-28 | Innopharma Inc | Stable bortezomib formulations |
CA2813003A1 (en) | 2010-10-05 | 2012-04-12 | Fresenius Kabi Usa, Llc | Bortezomib formulations stabilised with boric acid |
CA2866135A1 (en) | 2012-03-02 | 2014-09-06 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
EA021179B1 (ru) * | 2012-06-15 | 2015-04-30 | Ощество С Ограниченной Ответственностью "Тева" | Лиофилизат соединения бороновой кислоты |
CN103070835B (zh) * | 2013-01-31 | 2015-01-07 | 江苏奥赛康药业股份有限公司 | 一种含硼替佐米的冻干组合物及其制备方法 |
CN104586776B (zh) * | 2013-10-30 | 2017-05-17 | 扬子江药业集团上海海尼药业有限公司 | 以硼替佐米为活性成分的制剂及其制备方法 |
CN103720666B (zh) * | 2013-12-16 | 2015-11-25 | 亿腾药业(泰州)有限公司 | 一种注射用硼替佐米冻干制剂的制备方法 |
WO2016001905A2 (en) * | 2014-07-04 | 2016-01-07 | Dr. Reddy’S Laboratories Limited | Stable liquid ready-to-use injectable formulation of bortezomib |
EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
WO2016110870A1 (en) | 2015-01-07 | 2016-07-14 | Emcure Pharmaceuticals Limited | Pharmaceutical composition of bortezomid |
US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
KR101807462B1 (ko) | 2017-03-09 | 2017-12-08 | 씨제이헬스케어 주식회사 | 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법 |
RU2659160C1 (ru) * | 2017-07-10 | 2018-06-28 | Акционерное Общество "Фарм-Синтез" | Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом |
JP7423028B2 (ja) * | 2017-11-01 | 2024-01-29 | 日医工岐阜工場株式会社 | ボルテゾミブを含有する凍結乾燥医薬組成物 |
US11986486B2 (en) | 2020-11-02 | 2024-05-21 | Spes Pharmaceuticals Inc. | Aqueous compositions of bortezomib |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
WO2002059131A1 (en) * | 2001-01-25 | 2002-08-01 | Millennium Pharmaceuticals, Inc. | Formulation of boronic acid compounds |
US20060084592A1 (en) * | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
WO2006001956A2 (en) * | 2004-05-20 | 2006-01-05 | The Board Of Trustees Of The University Of Illinois | Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof |
WO2006001965A2 (en) | 2004-05-24 | 2006-01-05 | Abgenix, Inc. | Reducing the risk of human anti-human antibodies through v gene manipulation |
EA201070296A1 (ru) | 2007-08-21 | 2010-08-30 | Алза Корпорейшн | Липосомные композиции для введения in vivo соединений бороновой кислоты |
-
2010
- 2010-01-08 US US13/143,808 patent/US9095514B2/en not_active Expired - Fee Related
- 2010-01-08 EP EP10738286.3A patent/EP2379077A4/en not_active Withdrawn
- 2010-01-08 MX MX2011007192A patent/MX2011007192A/es not_active Application Discontinuation
- 2010-01-08 AU AU2010211981A patent/AU2010211981A1/en not_active Abandoned
- 2010-01-08 CA CA2748921A patent/CA2748921A1/en not_active Abandoned
- 2010-01-08 KR KR1020117015778A patent/KR20110114562A/ko not_active Application Discontinuation
- 2010-01-08 EA EA201170921A patent/EA201170921A1/ru unknown
- 2010-01-08 WO PCT/IN2010/000015 patent/WO2010089768A2/en active Application Filing
- 2010-01-08 CN CN2010800041181A patent/CN102292086B/zh not_active Expired - Fee Related
- 2010-01-08 JP JP2011544969A patent/JP5689816B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2010211981A1 (en) | 2011-08-18 |
CN102292086B (zh) | 2013-05-08 |
CA2748921A1 (en) | 2010-08-12 |
JP2012514633A (ja) | 2012-06-28 |
EP2379077A4 (en) | 2013-09-11 |
US20110275597A1 (en) | 2011-11-10 |
US9095514B2 (en) | 2015-08-04 |
KR20110114562A (ko) | 2011-10-19 |
EP2379077A2 (en) | 2011-10-26 |
WO2010089768A3 (en) | 2010-11-04 |
CN102292086A (zh) | 2011-12-21 |
EA201170921A1 (ru) | 2012-01-30 |
JP5689816B2 (ja) | 2015-03-25 |
WO2010089768A2 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007192A (es) | Composicion farmaceutica. | |
MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
MX342212B (es) | Inhibidores de neprilisina. | |
MY170935A (en) | Neprilysin inhibitors | |
TN2011000400A1 (en) | Inhibitors of beta-secretase | |
MX2013006802A (es) | Inhibidores de neprilisina. | |
GEP20146202B (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
MY165087A (en) | Neprilysin inhibitors | |
EA201270216A1 (ru) | Фармацевтический состав | |
NZ702749A (en) | Neprilysin inhibitors | |
MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
IN2014CN04530A (es) | ||
MY165918A (en) | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | |
GEP20146201B (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
IN2012DN02502A (es) | ||
UA109281C2 (uk) | Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль | |
MA33948B1 (fr) | Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. | |
TR201902057T4 (tr) | Tetrasiklin bileşikleri. | |
MY148393A (en) | Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
NZ707366A (en) | Novel histone deacetylase inhibitors and their use in therapy | |
MX2009010483A (es) | 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas. | |
MX2013008256A (es) | Derivados novedosos de tetrahidroquinolina. | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
MX346090B (es) | Derivados de pirrolidina usados como inhibidores de catepsina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |